secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quantum Cyber N.V. (QUCY)
CIK:        0001874252
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001213900-26-016890
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.02, 3.02, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mainz Biomed secures $6M private placement, names David Lazar Chairman; pivots to pancreatic cancer
--------------------------------------------------------------------------------

- First tranche of $3M closed Feb 13; second $3M expected after shareholder approval by April 15, 2026.
- Preferred shares convertible into up to 95%+ of fully diluted shares; Lazar appointed Chairman and gets board nomination rights.
- Company to focus on U.S. pancreatic cancer detection, evaluate sale of colorectal assets, wind down German sub.
- Settlement agreements with officers/directors require ~$1.9M aggregate payments upon final closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1874252/000121390026016890/0001213900-26-016890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1874252/000121390026016890/ea0277246-8k_mainz.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-016890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer